Results – Soothing efficacy – HYDRO-B18

All the participants completed the trial. Here are the summarizing tables of values. 

INDUCTION OF IRRITATION

SITE A: POSITIVE CONTROL

TIMING/PARAMETERS MEAN ST.DEV. P-VALUE SIGNIFICANCE
T0 – TEWL 12.6 4.26 p<0.0001*** yes
T0 – EI 252.35 47.78 p<0.0001*** yes

SITE B: NEGATIVE CONTROL

TIMING/PARAMETERS MEAN ST.DEV. P-VALUE SIGNIFICANCE
T0 – TEWL 7.38 1.82 p=0.004** yes
T0 – EI 183.05 47.66 p=0.9892 yes

SLS causes a significant disruption of the skin barrier resultant in an increase in TEWL values and in Erythema index.

ERYTHEMA INDEX

TIMING Δ% Site i/ Site A P-VALUE SIGNIFICANCE
SITE D: HYDRO-B18®
T0 -1% p=0.7660 no
T1 -3% p=0.6263 no
T2 -17% p=0.0110* yes
T3 -21% p=0.0094** yes
SITE E: BISABOLOL
T0 -1% p=0.9569 no
T1 0% p=0.9892 no
T2 -9% p=0.2339 no
T3 -16% p=0.0638 no
SITE F: AMMONIUM GLYCYRRHIZATE
T0 -2% p=0.6071 no
T1 -6% p=0.5250 no
T2 -16% p=0.0315* yes
T3 -14% p=0.0638 no

An increase of the index of erythema after SLS application is detected up to 24 hours (site A, t1). The product interrupts the increase in erythema index (site C, t2 e t3) more than standard Bisabolol (site D), Ammonium Glycyrrhizate (site E).

TRANSEPIDERMAL WATERLOSS

TIMING Δ% Site i/ Site A P-VALUE SIGNIFICANCE
SITE D: HYDRO-B18®
T0 -1% p=0.9784 no
T1 5% p=0.7150 no
T2 -16% p=0.0119* yes
T3 -9% p=0.3647 no
SITE E: BISABOLOL
T0 1% p=0.6848 no
T1 4% p=0.6949 no
T2 -15% p=0.0222* yes
T3 -10% p=0.2790 no
SITE F: AMMONIUM GLYCYRRHIZATE
T0 -2% p=0.4091 no
T1 -1% p=0.7049 no
T2 -14% p=0.0167* yes
T3 -11% p=0.1848 no
 

The product reduces the transepidermal water loss (TEWL) (site C, t2) as the Bisabolol (site D,t2) and Ammonium Glycyrrhizate do (site E,t2).

ERYTHEMA INDEX

TRANSEPIDERMAL WATERLOSS